Axon growth from limb motoneurons in the locust embryo: the effect of target limb removal on the path taken out of the central nervous system.

P. Whitington,E. Seifert

DOI: https://doi.org/10.1016/0012-1606(82)90252-4

IF: 3.148

1982-09-01

Developmental Biology

Abstract:

What problem does this paper attempt to address?

Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial

B Majorek-Olechowska,T Slomskis,L Zollerová,I Martín,C Sánchez,I Gilaberte,P Arranz,BILA-4021/PED Research Group

DOI: https://doi.org/10.18176/jiaci.1003

2024-05-10

Abstract:Background: Bilastine is a second-generation antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis (ARC) and urticaria in adults, adolescents, and children. The pharmacokinetics and safety of oral bilastine 10 mg/d in children aged 2 to 5 years were evaluated. Methods: This was a multicenter, open-label clinical trial in children aged 2 to 5 years with seasonal or perennial ARC or urticaria treated once daily with bilastine 10 mg orodispersible tablets. The safety evaluation included treatment-emergent adverse events (TEAEs), vital signs, and physical examination. Pharmacokinetic data were pooled with data from a prior pediatric study, and pharmacokinetic modeling was performed to assess consistency. Results: A total of 37 children with ARC (81.1%), urticaria (8.1%), or both (10.8%) were included in the study, with a mean (SD) age of 3.7 (1.2) years. The highest plasma concentrations of bilastine were observed 1 hour after administration (634.91 ng/mL). Eight patients (21.6%) experienced 1 TEAE each, none of which was severe. Body weight and age were not covariates of variation in either systemic clearance or the volume of distribution in children aged 2 to 5 years and did not affect the pharmacokinetic parameters of bilastine. Conclusions: The pharmacokinetics of bilastine was linear and consistent with data from a previous trial, suggesting that a 10-mg dose may be used in children (2 to <12 years). No dose adjustments are deemed necessary. Oral once-daily bilastine 10 mg presented a good safety profile in children aged 2 to 5.
Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: results from an international Delphi study

Giorgio Walter Canonica,Piotr Kuna,Marcus Maurer,Ralph Mösges,Zoltan Novak,Nikolaus Papadopoulos,Pablo Rodriguez Del Rio,Delphi Study Group

DOI: https://doi.org/10.7573/dic.2024-2-3

2024-05-01

Abstract:Background: Second-generation oral H1-antihistamines, including bilastine, represent the emerging treatments of allergic rhinitis (including rhinoconjunctivitis) and chronic urticaria in both adults and children. This study analyses available evidence supporting the use of bilastine amongst second-generation antihistamines for the symptomatic treatment of allergic rhinitis and urticaria in adults and children. Methods: Consensus amongst experts from 17 countries on the ideal treatment of rhinitis and urticaria, and the specific role of bilastine was measured by means of a modified Delphi process. A total of 12 statements were voted on by the experts using a five-point Likert scale (1 = strongly disagree; 2 = disagree; 3 = undecided; 4 = agree; 5 = strongly agree). The definition of consensus was set at a minimum of 80% concordance for 4+5 scores (agree or strongly agree). Results: All proposed statements reached consensus, with a concordance of ≥98% for five statements and ≥96% for seven. Conclusions: The wide consensus obtained for the proposed statements suggests a prominent role for bilastine in the management of allergic rhinitis and urticaria.
Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia

Wai Kwong Cheong,Alson Wai Ming Chan,Chin Chwen Ch'ng,Wen Hung Chung,Ma Teresita Gabriel,Kiran Godse,Wat Mitthamsiri,Hao Trong Nguyen,Marysia Tiongco-Recto,Dinesh Nagrale

DOI: https://doi.org/10.7573/dic.2021-12-2

2022-03-15

Abstract:Urticaria is a disabling condition, resulting in an impaired quality of life and sleep disruption, and can have an adverse impact on work-related or school-related performance and attendance. It is defined according to the presence of unknown (chronic spontaneous urticaria) or known (inducible urticaria) eliciting factors. Guidelines recommend second-generation H1-antihistamines for the first-line treatment of urticaria. Bilastine is indicated in adults, adolescents (aged ≥12 years) and children (aged ≥2 years (Mexico and some African countries), ≥4 years (Canada) or ≥6 years (Europe)) with a body weight of at least 20 kg for the symptomatic treatment of urticaria and allergic rhino-conjunctivitis. The aim of the Original Real-world cases of Bilastine In Treatment (ORBIT) study was to review real-world cases from across the Asia-Pacific region supported by evidence-based literature. Eight diverse, real-world, difficult-to-treat cases with urticaria in people aged 10-75 years are presented. Once-daily bilastine (20 mg (adults/adolescents) or 10 mg (children)) was found to be well tolerated and effective in the long-term management of chronic spontaneous urticaria and inducible urticaria.
Oxygen delivery and uptake by peripheral tissues: physiology and pathophysiology.

P. Schumacker,R. W. Samsel

DOI: https://doi.org/10.1016/S0749-0704(18)30435-4

IF: 3.879

1989-04-01

Critical Care Clinics

Abstract:
A Corporate Credit Rating Model Using Support Vector Domain Combined with Fuzzy Clustering Algorithm

Xuesong Guo,Zhengwei Zhu,Jia-lian Shi

DOI: https://doi.org/10.1155/2012/302624

2012-07-25

Abstract:Corporate credit-rating prediction using statistical and artificial intelligence techniques has received considerable attentions in the literature. Different from the thoughts of various techniques for adopting support vector machines as binary classifiers originally, a new method, based on support vector domain combined with fuzzy clustering algorithm for multiclassification, is proposed in the paper to accomplish corporate credit rating. By data preprocessing using fuzzy clustering algorithm, only the boundary data points are selected as training samples to accomplish support vector domain specification to reduce computational cost and also achieve better performance. To validate the proposed methodology, real-world cases are used for experiments, with results compared with conventional multiclassification support vector machine approaches and other artificial intelligence techniques. The results show that the proposed model improves the performance of corporate credit-rating with less computational consumption.
Assessment of functional capacity through oxygen consumption in patients with asymptomatic probable heart disease.

L. Rodrigues,E. Silami-Garcia,M. D. C. Moreira,Giane Amorim Ribeiro

DOI: https://doi.org/10.1590/S0066-782X1999000700001

1999-07-01

Arquivos Brasileiros de Cardiologia

Abstract:PURPOSE To compare peak exercise oxygen consumption (VO2peak) of healthy individuals with asymptomatic individuals with probable heart disease. METHODS Ninety-eight men were evaluated. They were divided into two groups: 1) 39 healthy individuals (group N) with an age range of 50 +/- 4.6 years; and 2) 59 asymptomatic individuals with signs of atherosclerotic and/or hypertensive heart disease (group C) with an age range of 51.9 +/- 10.4 years. In regard to age, height, body surface area, percentage of fat, lean body mass, and daily physical activity, both groups were statistically similar. Environmental conditions during the ergometric test were also controlled. RESULTS Maximal aerobic power (watts), VO2peak, maximal heart rate, and maximal pulmonary ventilation were lower in group C (p < 0.01) than in group N; weight, however, was lower in group N (p = 0.031) than in group C. Differences in the respiratory gas exchange index, heart rate at rest, and the maximal double product of the two groups were not statistically significant. CONCLUSION Signs of probable heart disease, even though asymptomatic, may reduce the functional capacity, perhaps due to the lower maximal cardiac output and/or muscle metabolic changes.
Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis

P J Gomes,J B Ciolino,P Arranz,G Hernández,N Fernández

DOI: https://doi.org/10.18176/jiaci.0894

2024-06-17

Abstract:Background and objective: Bilastine is a second-generation antihistamine approved for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. The present trial evaluated the efficacy and safety of a new bilastine 0.6% preservative-free eye drop formulation for the symptomatic treatment of allergic conjunctivitis. Methods: This phase 3, multicenter, double-masked, randomized study compared the efficacy, safety, and tolerability profile of bilastine 0.6% ophthalmic solution with that of ketotifen 0.025% and vehicle. The primary efficacy endpoint was reduction in ocular itching. The Ora-CAC® Allergen Challenge Model was used to assess ocular and nasal symptoms at 15 minutes (onset of action) and 16 hours after treatment. Results: Patients (N=228) were 59.6% male, and the mean (SD) age was 44.1 (13.4) years. Bilastine demonstrated efficacy in reducing ocular itching compared to vehicle at both onset of action and 16 hours after treatment (P<.001). Symptoms improved with ketotifen compared to vehicle 15 minutes after treatment (P<.001). Bilastine demonstrated statistical noninferiority to ketotifen for all 3 post-CAC timepoints at 15 minutes after instillation, based on an inferiority margin of 0.4. Compared with vehicle, bilastine improved in conjunctival redness, ciliary redness, episcleral redness, chemosis, eyelid swelling, tearing, rhinorrhea, ear and palate pruritus, and nasal congestion at 15 minutes after treatment (P<.05). Ophthalmic bilastine was safe and well tolerated. Mean drop comfort scores were significantly better for bilastine than for ketotifen immediately upon instillation (P<.05) and similar to those of vehicle. Conclusion: Ophthalmic bilastine effectively reduced ocular itching for 16 hours after administration, suggesting that it could be used as a once-daily treatment for the signs and symptoms of allergic conjunctivitis. ClinicalTrials.gov identifier: NCT03479307.
RHEUMATIC PNEUMONITIS Figure 3

R. Massumi,J. Legier

Abstract:IN THE COURSE of acute rheumatic fever the occurrence of pulmonary infiltrates is often considered a manifestation of pulmonary congestion, unrelated viral or bacterial pneumonitis, atelectasis, or infarction. These interpretations are undoubtedly correct frequently but cannot apply to all cases. Inasmuch as the pathologic process in acute rheumatic fever is known to be a diffuse one and capable of involving the vascular system and connective tissue in a wide variety of organ systems,1-4 the question of rheumatic pneumonitis may be logically advanced in such cases. The following presentation of two fatal cases with postmortem documentation and
Structure and Activity Changes of Phytohemagglutinin from Red Kidney Bean (Phaseolus vulgaris) Affected by Ultrahigh-Pressure Treatments.

Yunjun Lu,Cencen Liu,Mouming Zhao,Chun Cui,Jiaoyan Ren

DOI: https://doi.org/10.1021/acs.jafc.5b03337

IF: 6.1

2015-10-26

Journal of Agricultural and Food Chemistry

Abstract:Phytohemagglutin (PHA), purified from red kidney beans (Phaseolus vulgaris) by Affi-Gel blue affinity chromatography, was subjected to ultrahigh-pressure (UHP) treatment (150, 250, 350, and 450 MPa). The purified PHA lost its hemagglutination activity after 450 MPa treatment and showed less pressure tolerance than crude PHA. However, the saccharide specificity and α-glucosidase inhibition activity of the purified PHA did not change much after UHP treatment. Electrophoresis staining by periodic acid-Schiff (PAS) manifested that the glycone structure of purified PHA remained stable even after 450 MPa pressure treatment. However, electrophoresis staining by Coomassie Blue as well as circular dichroism (CD) and differential scanning calorimetry (DSC) assay proved that the protein unit structure of purified PHA unfolded when treated at 0-250 MPa but reaggregates at 250-450 MPa. Therefore, the hemagglutination activity tends to be affected by the protein unit structure, while the stability of the glycone structure contributed to the remaining α-glucosidase inhibition activity.
Proliferative phase endosperm promoters from Arabidopsis thaliana.

S. Tiwari,M. Spielman,Rob Day,R. Scott

DOI: https://doi.org/10.1111/J.1467-7652.2006.00189.X

IF: 13.8

2006-07-01

Plant Biotechnology Journal

Abstract:Endosperm accounts for a large proportion of human nutrition and is also a major determinant of seed viability and size, not only in cereals, but also in species with ephemeral endosperms, such as soybean and oilseed rape. The extent of endosperm proliferation early in seed development is a crucial component in setting seed size; therefore, a biotechnological approach for the modification of this trait requires promoters active in early endosperm. To find such promoters, we constructed an array based on cDNAs extracted from developing Arabidopsis seeds enriched for proliferating endosperm. Hybridization with RNA extracted from vegetative and reproductive tissues, including endosperm, and subsequent data filtering yielded sets of endosperm-expressed and endosperm-preferred genes, including many hundreds not previously identified in array experiments designed to detect genes expressed in Arabidopsis seeds. Of eight promoters selected for validation, seven were active in early endosperm, three with no detected activity elsewhere in the plant. Therefore, this strategy has yielded proliferative phase endosperm promoters which should be useful in altering seed size.
Metamers of the ventral stream revisited.

Thomas S. A. Wallis,M. Bethge,Felix Wichmann

DOI: https://doi.org/10.1167/15.12.554

2015-09-01

Journal of Vision

Abstract:Peripheral vision has been characterised as a lossy representation: information present in the periphery is discarded to a greater degree than in the fovea. What information is lost and what is retained? Freeman and Simoncelli (2011) recently revived the concept of metamers (physically different stimuli that look the same) as a way to test this question. Metamerism is a useful criterion, but several details must be refined. First, their paper assessed metamerism using a task with a significant working memory component (ABX). We use a purely spatial discrimination task to probe perceptual encoding. Second, a strong test of any hypothesised representation is to what extent it is metameric for a real scene. Several subsequent studies have misunderstood this to be the result of the paper. Freeman and Simoncelli instead only compared synthetic stimuli to each other. Pairs of stimuli were synthesised from natural images such that they were physically different but equal under the model representation. The experiment then assessed the scaling factor (spatial pooling region as a function of retinal eccentricity) required to make these two synthesised images indiscriminable from one another, finding that these scaling factors approximated V2 receptive field sizes. We find that a smaller scale factor than V2 neurons is required to make the synthesised images metameric for natural scenes (which are also equal under the model). We further show that this varies over images and is modified by including the spatial context of the target patches. While this particular model therefore fails to capture some perceptually relevant information, we believe that testing specific models against the criteria that they should discard as much information as possible while remaining metameric is a useful way to understand perceptual representations psychophysically. Meeting abstract presented at VSS 2015.
Goblet cell carcinoid of appendix. Ultrastructural features and histogenetic aspects

T. Warner,I. Seo

DOI: https://doi.org/10.1002/1097-0142(197911)44:5<1700::AID-CNCR2820440525>3.0.CO;2-T

IF: 6.9209

1979-11-01

Cancer

Abstract:Light and electron microscopic examination of a goblet cell carcinoid revealed cells with pleomorphic neurosecretory‐type granules, cells containing mucin some of which also contained these granules and less differentiated cells lacking the aforementioned features. Recent embryologic and anatomic studies of developing avian and mammalian gut, respectively, show that intestinal APUD cells are probably of endodermal origin. Therefore, mixed carcinoid tumors such as the goblet cell variant could arise in crypt base stem cells.
Comparison of the Efficacy and Safety of Bilastine 20 mg versus Fexofenadine 180 mg for Treatment of Perennial Allergic Rhinitis: Randomized Controlled Study

Aditya Singhal,Pooja Agrawal,Probal Chatterji,Pritpal Singh Matreja,Tariq Mahmood

DOI: https://doi.org/10.1007/s12070-024-04770-0

Abstract:Background: Antihistamines has always remained the mainstay drug treatment for Allergic Rhinitis (AR). Bilastine is a novel, non-sedative antihistamine with a super-selective H1 receptor antagonist property. Both bilastine and fexofenadine are second generation antihistamine drugs commonly used to manage AR and Chronic Urticaria (CU). Autologous Skin Serum Test (ASST) is a practical test for histamine release in CU. These tests have been studied in AR patients with limited data studies. Methods: 114 patients diagnosed with perennial AR were recruited and divided into two groups of 57 each. One group was started Bilastine 20 mg once a day and other group, fexofenadine 180 mg once a day. Total Nasal Symptom Score (TNSS) was calculated at presentation and two weeks of antihistamine therapy. ASST was hypothesized to be the test for AR and performed at the time of presentation and at two weeks follow-up. Intergroup and Intragroup assessment of TNSS, ASST and its variables were done using unpaired and paired t test respectively. Results: Patients showed reduction in symptoms of AR with both antihistamines. A significant improvement of sneezing and rhinorrhoea was seen in Fexofenadine group as compared to Bilastine group. TNSS showed statistically significant improvement in both the groups. ASST had statistically significant reduction in both the groups. Conclusions: Both Bilastine and fexofenadine were found to be effective in reduction of symptoms of allergic rhinitis. Bilastine was found to be more effective in overall as well as sneezing and rhinorrhoea noted two weeks after therapy. Supplementary information: The online version contains supplementary material available at 10.1007/s12070-024-04770-0.
A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria

Bela Shah,Dhiraj Dhoot,Ankita Choudhary,Neha Jangid,Deval Mistry,Shikha Shah,Shruti Kamat,Hanmant Barkate

DOI: https://doi.org/10.2147/CCID.S350122

2022-02-18

Abstract:Introduction: Though second-generation antihistamines (SGAH) are first-line drugs in chronic spontaneous urticaria (CSU), 50% of patients do not respond to them. In such patients, guidelines recommend either up-dosing of SGAH or combination of different antihistamines. However, the studies comparing these treatment regimens are limited. Methods: In this comparative, three-arm study, CSU patients were randomized to receive standard dose of either bilastine, fexofenadine, or levocetirizine for 2 weeks. After 2 weeks of treatment, non-responders received double dose of either bilastine or fexofenadine, while hydroxyzine 25 mg once daily was added in the levocetirizine group. Patients were primarily evaluated for improvement in CSU, quality of life, and somnolence. Results: A total of 110 patients with CSU were recruited. At the end of 4 weeks, 33/39, 26/35, and 22/36 patients in the bilastine, fexofenadine, and levocetirizine groups showed improvement in urticaria symptoms. At week 2, there was no statistical difference in urticaria activity score (UAS7) improvement between any of the groups; however, at week 4, there was a statistical difference between the bilastine and levocetirizine groups (p<0.05). Somnolence was significantly lower in the bilastine group (p<0.05). Bilastine was statistically significant (p<0.05) in the improvement of quality of life as compared to both groups. No major adverse events were reported during study period; however, bilastine was associated with significantly lower levels of AEs compared to levocetirizine (p<0.05). Conclusion: Two-fold up-dosing of bilastine improves CSU symptoms without compromising safety as compared to two-fold up-dosing of fexofenadine and combination of first- and second-generation antihistamines.
Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis

Xiali Xue,Qiyin Wang,Xinwei Yang,Huan Tu,Zhongyi Deng,Dezhi Kong,Wanna Liu,Zhonghe Fan,Ning Li

DOI: https://doi.org/10.1159/000527181

Abstract:Background: Allergic diseases are a public health problem with the largest number of patients and the widest age distribution. Chronic urticaria (CU) is a common clinical allergic disease. Bilastine is effective in the treatment of CU, especially skin wind masses and erythema. The purpose of this study was to systematically evaluate the efficacy and safety of Bilastine in the treatment of CU symptoms and to provide an evidence-based reference for clinical rational drug use. Methods: PubMed, Scopus, the Cochrane Library, Embase, EBSCO, and other databases were searched by computer to collect the trials on the effect of bilastine on patients with CU. The retrieval time limit was established until November 2021. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias in the included study. Meta-analysis was performed using RevMan5.4 software. Results: A total of 7 studies were included, including 975 patients. Meta-analysis results showed that compared to the control group, bilastine significantly improved the skin quality of life index, Total Symptom Score (TSS), and weekly urticaria activity score. The skin quality of life index DLQI score (MD = -4.98, 95% CI: -8.09 to -1.86, p = 0.002), skin symptom score TSS (MD = -1.62, 95% CI -2.29 to -0.94, p < 0.00001), the number of hives in a week UAS-7 score (MD = -25.28, 95% CI -32.36 to -18.19, p < 0.00001), and the differences were statistically significant. Conclusions: Bilastine has a better therapeutic effect on CU and can also significantly improve the clinical symptoms and quality of life of CU.
Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital.

P. Mazza,Emmanuela Secondo,G. Palazzo,B. Amurri,N. Manna,Gianfranco Miloro,R. Moscogiuri

Haematologica

Abstract:BACKGROUND AND OBJECTIVE Analysis of costs of high technological procedures such as peripheral blood stem cell (PBSC) autotransplantation in lymphomas are generally finalized at disclosing whether the improvement of survival in a subset of patients is cost effective and whether the cost of the procedure could be reduced. With the aim of revealing a possibility of reducing costs with respect to conditions of safety, we present our experience with PBSC autotransplantation in a particularly poor prognosis subset of patients with lymphoma. DESIGN AND METHODS The expenses are analyzed for groups of cost and main resources necessary at unitary cost are considered separately. Groups of cost include various phases of the PBSC autotransplantation such as preparative procedures, execution of myeloablative therapy, reinfusion of CD34 cells, supportive therapy after reinfusion until discharge of the patient, general support for the management of patient. All costs are calculated according to 1997 prices and salaries and reported in dollars. The analysis was conducted on 21 patients with lymphoma resistant to other therapies treated by myeloablative therapy and PBSC autotransplantation in an hematologic unit in an open ward; the assistance was provided by staff not exclusively dedicated to bone marrow transplant procedures, with some help from a family member. RESULTS The PBSC procedure, including all phases, costs from $17,761.9 to $18,259.9 depending on the type of myeloablative therapy employed; the mean cost was $18,092.6. The preparative phase with mobilization of CD34 cells, cryopreservation and reinfusion costed $3,538.7 (19.6% of the total cost); a major cost of this phase was cryopreservation and CD34 manipulation ($857.1). The second phase with myeloablative therapy and reinfusion of CD34 cells had a mean cost of $2,785.9 (15.4% of the total cost); a major cost of this phase was the hospitalization ($1,119.8). The third phase of patient's support after treatment had a total cost of $7,649 (42.3% of the cost of the total procedure) with the major cost being due to hospitalization ($2,571) calculated on a mean of 15 days after the reinfusion of CD-34. The last group of costs, including management support, accounted for $4,119 (22.7%) with a major cost being amortization of the structure ($1,600). The general cost for nurse's assistance to the patient was $1,355.1 (7.5%). INTERPRETATION AND CONCLUSIONS A procedure of PBSC autotransplantation in resistant lymphoma is affordable without the strict precautions generally given in intensive care units. This provides a substantial reduction of expenses because of the low number of specifically trained staff members and the generally low cost of the necessary supplies. Before, however, proposing PBSC autotransplantation in most patients with resistant lymphoma, an evaluation of whether costs could be further reduced and whether the procedure has a cost benefit impact is needed.
Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study

Vishakha V Sinha,Mrunalini Vinay Kalikar,Jayesh Ishwardas Mukhi,Akhil Bhagwan Giradkar,Smita Sontakke

DOI: https://doi.org/10.4103/picr.picr_28_23

Abstract:Purpose: Bilastine is a novel second-generation antihistaminic. Very few studies in Indian population have compared the safety and efficacy of bilastine with other second-generation antihistaminic like cetirizine. Hence, the present study was planned. Materials and methods: This was a randomized, open-label comparative parallel group study conducted on 70 patients of chronic spontaneous urticaria (CSU). Patients either received cetirizine 10 mg or bilastine 20 mg once daily for 6 weeks. The primary endpoint was to find out the difference in the mean total symptom score (MTSS) at baseline and 6 weeks. The secondary endpoint was to find out changes in the scale of the number of wheals, change in pruritus scale, scale for size of wheal, change for interference of wheals with sleep, change in visual analog scale (VAS) for sedation, change in scale for intensity of erythema, and change in Scale for Extent of Skin Area Involvement (SESI). Results: Bilastine and cetirizine offer a significant reduction in MTSS, mean number of wheals, and mean pruritus scale at baseline to 1, 3, and 6 weeks. The mean difference in MTSS was significantly more in bilastine. Cetirizine showed a significant increase in VAS score for sedation as compared to bilastine. Both the drugs were well tolerated and safe. Adverse events like headache, gastric irritation, dryness of mouth, and sedation were more reported in cetirizine group. Conclusion: Bilastine was more efficacious than cetirizine in patients of CSU and the efficacy was seen earlier at 1 week, which was not seen in the cetirizine group.
Electrophoretic mobility shift in native gels indicates calcium-dependent structural changes of neuronal calcium sensor proteins.

Jeffrey Viviano,A. Krishnan,Hao-bin Wu,V. Venkataraman

DOI: https://doi.org/10.1016/j.ab.2015.11.005

IF: 2.9

2016-02-01

Analytical Biochemistry

Abstract:
Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose

Abhishek De,Bela Shah,Pravin D Banodkar,Dhiraj Dhoot,Kruttika Chitnis,Hanmant Barkate

DOI: https://doi.org/10.4103/ijd.ijd_89_23

Abstract:Background: Although second-generation antihistamines (SGAHs) are recommended as first-line drugs in chronic spontaneous urticaria (CSU), symptom relief has been reported in <50% of patients at licensed doses and up to fourfold dosing is recommended for these patients. Bilastine (SGAH), at licensed doses and higher doses, is efficacious in CSU. However, large-scale real-world data is scarce. Objectives: To report the real-world evidence of the safety and effectiveness of bilastine at a double dose (40-mg per day) in CSU management. Materials and methods: In this retrospective questionnaire-based study carried out from February 2022 to July 2022, a pre-validated questionnaire was used to gather data on patients with CSU in dermatology practice from 62 centres across India. Adult patients of either gender diagnosed with CSU and switched over to bilastine 40 mg/day due to a non-satisfactory response (UCT score <12) to other antihistamines at double dose were considered for analysis. Based on UCT scores, patients were classified as responders (UCT ≥12) and non-responders at follow-up assessment at 2 weeks as compared to baseline. Results: 177 patients with a mean disease duration of 2.11 ± 1.48 years were included in the final analysis, with 53% females and 47% males. At the end of two weeks, 74/177 (42%) patients were classified as responders, and 103/177 (58%) were non-responders to Bilastine 40 mg/day. The mean change of UCT score from 5.0 ± 2.2 at baseline to 8.08 ± 5.41 (62% improvement) was significant (P < 0.001). Sedation was reported by ten patients without any discontinuation of treatment. Conclusion: Bilastine 40 mg/day was effective and well-tolerated in controlling CSU symptoms refractory to antihistamines at double doses.
Sandfly fever epidemiology in Croatia.

B. Borčić,V. Punda

Abstract:

Axon growth from limb motoneurons in the locust embryo: the effect of target limb removal on the path taken out of the central nervous system.

Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial

Bilastine for the treatment of allergic rhinoconjunctivitis and urticaria: results from an international Delphi study

Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia

Oxygen delivery and uptake by peripheral tissues: physiology and pathophysiology.

A Corporate Credit Rating Model Using Support Vector Domain Combined with Fuzzy Clustering Algorithm

Assessment of functional capacity through oxygen consumption in patients with asymptomatic probable heart disease.

Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis

RHEUMATIC PNEUMONITIS Figure 3

Structure and Activity Changes of Phytohemagglutinin from Red Kidney Bean (Phaseolus vulgaris) Affected by Ultrahigh-Pressure Treatments.

Proliferative phase endosperm promoters from Arabidopsis thaliana.

Metamers of the ventral stream revisited.

Goblet cell carcinoid of appendix. Ultrastructural features and histogenetic aspects

Comparison of the Efficacy and Safety of Bilastine 20 mg versus Fexofenadine 180 mg for Treatment of Perennial Allergic Rhinitis: Randomized Controlled Study

Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis

Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital.

Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study

Electrophoretic mobility shift in native gels indicates calcium-dependent structural changes of neuronal calcium sensor proteins.

Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose

Sandfly fever epidemiology in Croatia.